Yurut-Caloglu V, Haydaroglu A, Ozkok S, Yalman D, Bolukbasi Y
Trakya University Hospital, Department of Radiation Oncology, Edirne, Turkey.
J BUON. 2009 Jul-Sep;14(3):519-21.
To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT).
Thirteen consecutive patients were included. All of them had measurable tumor before RT. 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 days before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT.
Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during RT was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034).
rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.
评估重组人促红细胞生成素（rhEPO）对于接受放疗（RT）的肺癌患者低血红蛋白（Hb）水平、总体肿瘤缓解率及rhEPO不良事件的有效性。
纳入连续的13例患者。所有患者在放疗前均有可测量的肿瘤。在放疗前7 - 10天，每周3次给予150 IU/kg的α-或β- rhEPO。目标Hb值为13 g/dl。放疗结束6周后评估肿瘤反应。
62%（n = 8）的患者对rhEPO有反应。每周平均Hb增加值为0.69 g/dl（范围0.42 - 1）。有反应的患者放疗期间平均Hb值为13.2 g/dl（范围9 - 14.7），无反应的患者为10.7 g/dl（范围9.7 - 11.8）（p = 0.005）。有反应的患者对放疗的总体缓解率显著高于无反应的患者（p = 0.034）。
rhEPO可提高接受放疗的肺癌患者的Hb水平。然而，安全性，更重要的是，适应证需要进一步明确。
